MRE11抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using MRE11 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of K562 cells using MRE11 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human bladder cancer tissues using MRE11 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human ovarian cancer tissues using MRE11 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectum cancer tissues using MRE11 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded rat brain tissues using MRE11 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded rat cerebellum tissues using MRE11 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded rat kidney tissues using MRE11 mouse mAb with DAB staining.    

  
  

The MRE11 antibody is a crucial tool in molecular biology and cancer research, targeting the MRE11 protein encoded by the *MRE11A* gene. MRE11 forms the MRE11-RAD50-NBS1 (MRN) complex, a central player in DNA damage response (DDR), particularly in repairing double-strand breaks (DSBs) via homologous recombination (HR) and non-homologous end joining (NHEJ). This nuclease also activates cell cycle checkpoints and stabilizes replication forks. Antibodies against MRE11 enable detection of its expression, localization, and post-translational modifications in cells and tissues, using techniques like immunoblotting, immunofluorescence, and immunohistochemistry.

In cancer research, MRE11 antibodies help assess DDR deficiencies linked to genomic instability and tumorigenesis. Reduced MRE11 expression or mutations correlate with poor prognosis in cancers (e.g., breast, ovarian) and sensitivity to therapies like PARP inhibitors or radiation. Dysfunctional MRE11 is also implicated in hereditary disorders such as ataxia-telangiectasia-like disorder (ATLD) and Nijmegen breakage syndrome. Researchers use these antibodies to study MRN complex dynamics, interactions with DDR proteins (e.g., BRCA1. ATM), and responses to genotoxic agents. Additionally, MRE11 antibodies serve as biomarkers in clinical studies to stratify patients for targeted therapies or predict treatment resistance. However, variability in antibody specificity requires careful validation to avoid cross-reactivity with homologous proteins. Overall, MRE11 antibodies are indispensable for unraveling DNA repair mechanisms and advancing precision oncology.